Breast Cancer Clinical Trials in Pittsburgh

Showing 141-160 of 614 trials

MARGetuximab Or Trastuzumab (MARGOT)

NCT04425018

The purpose of this study is to determine how well participants with stage II-III HER2-positive breast cancer respond to pre-operative treatment using one of two different combinations of drugs. Drugs and Combinations used: * Paclitaxel, Pertzumab and Margetuximab (Margenza) * Paclitaxel, Pertzumab and Trastuzumab (Herceptin)

Breast CancerStage II Breast CancerStage III Breast Cancer+1 more

Dana-Farber Cancer Institute174 participantsStarted Jul 2020

Washington D.C., District of Columbia, United States • Washington D.C., District of Columbia, United States • Boston, Massachusetts, United States +11 more locations

Active Not RecruitingPhase 2< 1 mile

Carboplatin and Paclitaxel With or Without Atezolizumab Before Surgery in Treating Patients With Newly Diagnosed, Stage II-III Triple-Negative Breast Cancer

NCT02883062

This phase II trial studies how well carboplatin and paclitaxel with or without atezolizumab before surgery works in treating patients with newly diagnosed, stage II-III triple negative breast cancer. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving carboplatin and paclitaxel with or without atezolizumab before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed.

Invasive Breast CarcinomaStage II Breast Cancer AJCC v6 and v7Stage III Breast Cancer AJCC v7+1 more

National Cancer Institute (NCI)67 participantsStarted Aug 2017

Phoenix, Arizona, United States • Scottsdale, Arizona, United States • Sacramento, California, United States +11 more locations

MARGetuximab Or Trastuzumab (MARGOT)

Carboplatin and Paclitaxel With or Without Atezolizumab Before Surgery in Treating Patients With Newly Diagnosed, Stage II-III Triple-Negative Breast Cancer

Breast Cancer Trials in Other Cities

Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies

CEM to Reduce Biopsy Rates for Less Than Highly Suspicious Breast Abnormalities: a Prospective Study

Study of AVZO-021 in Patients With Advanced Solid Tumors

LS301-IT in Partial Mastectomy and Sentinel Lymph Node Biopsy (SLNB) for DCIS or Stage I-II Primary Invasive Breast Cancer

ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer

Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression

A Study of XMT-1660 in Participants With Solid Tumors

First-in-human Study of DS-1062a for Advanced Solid Tumors (TROPION-PanTumor01)

TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd

A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer

STEMVAC in Patients With Early Stage Triple Negative Breast Cancer

Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer

Phase 1/2 Study of Amcenestrant (SAR439859) Single Agent and in Combination With Other Anti-cancer Therapies in Postmenopausal Women With Estrogen Receptor Positive Advanced Breast Cancer

A Study of Zilovertamab Vedotin (MK-2140/VLS-101) in Participants With Solid Tumors (MK-2140-002)

Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer

Women Informed to Screen Depending on Measures of Risk (Wisdom Study)

A Study of PF-06873600 in People With Cancer

A Study of LY3484356 in Women With Breast Cancer Before Having Surgery

Other Conditions in Pittsburgh